1 research outputs found
Supplementary Material for: Proteomic Analysis of Pancreatic Ductal Adenocarcinoma Compared with Normal Adjacent Pancreatic Tissue and Pancreatic Benign Cystadenoma
<p><i>Background:</i> Dual expression of potential biomarkers in both
benign and malignant pancreatic tumors was a major obstacle in the
development of diagnostic biomarkers of early pancreatic cancer. <i>Methods:</i>
To better understand the limitations of potential protein biomarkers in
pancreatic cancer, we employed two-dimensional difference gel
electrophoresis technology and tandem mass spectrometry to study protein
expression profiles in pancreatic cancer tissues, benign pancreatic
adenoma and normal adjacent pancreas. Seven differently expressed
proteins were selected for validation by Western blot and/or
immunohistochemistry. <i>Results:</i> 21 spots were overexpressed and 24
spots were downexpressed in pancreatic cancer compared with benign and
normal adjacent tissues. Our study demonstrated that three candidate
pancreatic ductal adenocarcinoma biomarkers identified in previous
studies, fructose-bisphosphate aldolase A, α-smooth muscle actin and
vimentin, were also overexpressed in pancreatic cystadenoma, which might
lower their further utility as biomarkers for pancreatic cancer.
Aflatoxin B<sub>1</sub> aldehyde reductase (AKR7A2) was confirmed to be
only highly expressed in pancreatic cancer, not in normal adjacent
pancreas and benign tumors. <i>Conclusions:</i> The protein profile
pattern of pancreatic cystadenoma was more similar to normal adjacent
pancreas than pancreatic cancer. We identified panels of the upregulated
proteins in pancreatic cancer, which have not been reported in prior
proteomic studies. AKR7A2 may be a novel potential biomarker for
pancreatic cancer.</p